Free Trial
NASDAQ:TRVN

Trevena Q3 2024 Earnings Results & Report

Trevena logo
$0.07 0.00 (0.00%)
As of 10/12/2026 02:57 PM Eastern

Trevena reported Q3 2024 earnings on November 7, 2024. The company reported EPS of -$5.79, while revenue was $0.28 million.

Earnings Announcement Details

Quarter
Q3 2024
Report Date

Trevena EPS Results

Actual EPS
-$5.79
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Trevena Revenue Results

Actual Revenue
$0.28 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Trevena's next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules.

Conference Call Resources

Trevena Q3 2024 Earnings FAQ

Trevena (NASDAQ:TRVN) reported earnings of -$5.79 per share for Q3 2024. The report was announced on Thursday, November 7, 2024.

Trevena reported revenue of $0.28 million for Q3 2024.

Trevena's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Trevena on the company's earnings history page.

Trevena Earnings Headlines

Trevena Inc.
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
Trevena, Inc. (TRVN) - Yahoo Finance
See More Trevena Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Trevena? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Trevena and other key companies, straight to your email.

About Trevena

Trevena (NASDAQ:TRVN) is a biopharmaceutical company focused on developing medicines for central nervous system disorders, with an emphasis on addressing the limitations of existing opioid and other neurological therapies. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Trevena’s principal commercial product is OLINVYK (oliceridine) injection, an intravenous opioid approved by the U.S. Food and Drug Administration for the management of acute pain in adults severe enough to require an intravenous opioid analgesic. OLINVYK was designed to provide pain relief while potentially reducing certain adverse effects associated with conventional opioids, although it carries the risks and precautions associated with opioid medicines.

The company has also researched additional compounds for neurological conditions, including investigational therapies intended for disorders such as pain and epilepsy. Trevena’s commercial activities have primarily focused on the United States, while its development and licensing efforts have included relationships intended to support access to international markets. Information about the company’s current leadership and operating status may change over time.

View Trevena Profile